BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sultana A, Tudur Smith C, Cunningham D, Starling N, Tait D, Neoptolemos JP, Ghaneh P. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007;96:1183-90. [PMID: 17406358 DOI: 10.1038/sj.bjc.6603719] [Cited by in Crossref: 154] [Cited by in F6Publishing: 136] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Eskander MF, Bliss LA, Tseng JF. Pancreatic adenocarcinoma. Current Problems in Surgery 2016;53:107-54. [DOI: 10.1067/j.cpsurg.2016.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
2 Leenhardt R, Camus M, Mestas JL, Jeljeli M, Abou Ali E, Chouzenoux S, Bordacahar B, Nicco C, Batteux F, Lafon C, Prat F. Ultrasound-induced Cavitation enhances the efficacy of Chemotherapy in a 3D Model of Pancreatic Ductal Adenocarcinoma with its microenvironment. Sci Rep 2019;9:18916. [PMID: 31831785 DOI: 10.1038/s41598-019-55388-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Takaori K, Bassi C, Biankin A, Brunner TB, Cataldo I, Campbell F, Cunningham D, Falconi M, Frampton AE, Furuse J, Giovannini M, Jackson R, Nakamura A, Nealon W, Neoptolemos JP, Real FX, Scarpa A, Sclafani F, Windsor JA, Yamaguchi K, Wolfgang C, Johnson CD;  IAP/EPC study group on the clinical managements of pancreatic cancer. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology. 2016;16:14-27. [PMID: 26699808 DOI: 10.1016/j.pan.2015.10.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
4 Halfdanarson TR, Haraldsdottir S, Borad MJ. Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Res 2013;2:105. [PMID: 24327864 DOI: 10.12688/f1000research.2-105.v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Kim SS, Lee S, Lee HS, Bang S, Park MS. Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy. Abdom Radiol (NY) 2021;46:655-66. [PMID: 32748250 DOI: 10.1007/s00261-020-02661-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Bjerregaard JK, Mortensen MB, Jensen HA, Nielsen M, Pfeiffer P. Prognostic Factors for Survival and Resection in Patients With Initial Nonresectable Locally Advanced Pancreatic Cancer Treated With Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics 2012;83:909-15. [DOI: 10.1016/j.ijrobp.2011.09.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
7 Renouf D, Moore M. Evolution of systemic therapy for advanced pancreatic cancer. Expert Rev Anticancer Ther 2010;10:529-40. [PMID: 20397918 DOI: 10.1586/era.10.21] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
8 Khan K, Cunningham D, Peckitt C, Barton S, Tait D, Hawkins M, Watkins D, Starling N, Rao S, Begum R, Thomas J, Oates J, Guzzardo V, Fassan M, Braconi C, Chau I. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget 2016;7:12672-81. [PMID: 26862857 DOI: 10.18632/oncotarget.7208] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
9 Graham JS, Jamieson NB, Rulach R, Grimmond SM, Chang DK, Biankin AV. Pancreatic cancer genomics: where can the science take us? Clin Genet 2015;88:213-9. [PMID: 25388820 DOI: 10.1111/cge.12536] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
10 Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, Cunningham D, Falk S, Wadd N, Harrison M, Corrie P, Iveson T, Robinson A, McAdam K, Eatock M, Evans J, Archer C, Hickish T, Garcia-Alonso A, Nicolson M, Steward W, Anthoney A, Greenhalf W, Shaw V, Costello E, Naisbitt D, Rawcliffe C, Nanson G, Neoptolemos J. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15:829-840. [PMID: 24954781 DOI: 10.1016/s1470-2045(14)70236-0] [Cited by in Crossref: 186] [Cited by in F6Publishing: 107] [Article Influence: 23.3] [Reference Citation Analysis]
11 Kong X, Li L, Li Z, Xie K. Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. Cytokine Growth Factor Rev 2012;23:343-56. [PMID: 22749856 DOI: 10.1016/j.cytogfr.2012.06.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
12 Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Maréchal R, Van Laethem JL, Ducreux M. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016;57:10-22. [PMID: 26851397 DOI: 10.1016/j.ejca.2015.12.026] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 14.2] [Reference Citation Analysis]
13 Huguet F, Orthuon A, Touboul E, Marseguerra R, Mornex F. [Pancreatic cancer]. Cancer Radiother 2010;14 Suppl 1:S94-102. [PMID: 21129675 DOI: 10.1016/S1278-3218(10)70012-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
14 Zhu CP, Shi J, Chen YX, Xie WF, Lin Y. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol. 2011;99:108-113. [PMID: 21571383 DOI: 10.1016/j.radonc.2011.04.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.0] [Reference Citation Analysis]
15 Hill EJ, Nicolay NH, Middleton MR, Sharma RA. Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research? Crit Rev Oncol Hematol 2012;83:353-87. [PMID: 22309673 DOI: 10.1016/j.critrevonc.2011.12.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
16 Sajjad M, Batra S, Hoffe S, Kim R, Springett G, Mahipal A. Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis. Am J Clin Oncol 2018;41:236-41. [PMID: 26796313 DOI: 10.1097/COC.0000000000000261] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
17 Ambe C, Fulp W, Springett G, Hoffe S, Mahipal A. A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. J Gastrointest Canc 2015;46:284-90. [DOI: 10.1007/s12029-015-9734-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
18 Gunnlaugsson A, Anderson H, Lind P, Glimelius B, Johnsson A. Multicentre phase I–II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. Radiotherapy and Oncology 2010;95:292-7. [DOI: 10.1016/j.radonc.2010.04.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
19 KalantarMotamedi Y, Choi RJ, Koh SB, Bramhall JL, Fan TP, Bender A. Prediction and identification of synergistic compound combinations against pancreatic cancer cells. iScience 2021;24:103080. [PMID: 34585118 DOI: 10.1016/j.isci.2021.103080] [Reference Citation Analysis]
20 Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut. 2007;56:1134-1152. [PMID: 17625148 DOI: 10.1136/gut.2006.103333] [Cited by in Crossref: 84] [Cited by in F6Publishing: 179] [Article Influence: 5.6] [Reference Citation Analysis]
21 Wong HH, Lemoine NR. Biological approaches to therapy of pancreatic cancer. Pancreatology. 2008;8:431-461. [PMID: 18724071 DOI: 10.1159/000151536] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
22 Rembielak AI, Jain P, Jackson AS, Green MM, Santorelli GR, Whitfield GA, Crellin A, Garcia-Alonso A, Radhakrishna G, Cullen J, Taylor MB, Swindell R, West CM, Valle J, Saleem A, Price PM. Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. Transl Oncol 2014;7:55-64. [PMID: 24772208 DOI: 10.1593/tlo.13724] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
23 Mancini BR, Stein S, Lloyd S, Rutter CE, James E, Chang BW, Lacy J, Johung KL. Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. J Gastrointest Oncol 2018;9:982-8. [PMID: 30603116 DOI: 10.21037/jgo.2018.04.03] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Goji T, Kimura T, Miyamoto H, Takehara M, Kagemoto K, Okada Y, Okazaki J, Takaoka Y, Miyamoto Y, Mitsui Y, Matsumoto S, Sueuchi T, Tanaka K, Fujino Y, Takaoka T, Kitamura S, Okamoto K, Kimura M, Sogabe M, Muguruma N, Okahisa T, Sato Y, Sagawa T, Fujikawa K, Sato Y, Ikushima H, Takayama T. A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. Cancer Chemother Pharmacol 2015;76:615-20. [PMID: 26220846 DOI: 10.1007/s00280-015-2835-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
25 Park W, Chawla A, O'Reilly EM. Pancreatic Cancer: A Review. JAMA 2021;326:851-62. [PMID: 34547082 DOI: 10.1001/jama.2021.13027] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Perinel J, Adham M. Palliative therapy in pancreatic cancer-palliative surgery. Transl Gastroenterol Hepatol 2019;4:28. [PMID: 31231695 DOI: 10.21037/tgh.2019.04.03] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
27 Páez D, Labonte MJ, Lenz HJ. Pancreatic cancer: medical management (novel chemotherapeutics). Gastroenterol Clin North Am. 2012;41:189-209. [PMID: 22341258 DOI: 10.1016/j.gtc.2011.12.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
28 Humbert M, Castéran N, Letard S, Hanssens K, Iovanna J, Finetti P, Bertucci F, Bader T, Mansfield CD, Moussy A. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS One. 2010;5:e9430. [PMID: 20209107 DOI: 10.1371/journal.pone.0009430] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
29 Zhu X, Shi D, Li F, Ju X, Cao Y, Shen Y, Cao F, Qing S, Fang F, Jia Z, Zhang H. Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer. Cancer Med 2018. [PMID: 29771005 DOI: 10.1002/cam4.1553] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
30 Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72. [DOI: 10.1038/nrclinonc.2009.236] [Cited by in Crossref: 516] [Cited by in F6Publishing: 504] [Article Influence: 43.0] [Reference Citation Analysis]
31 Sahora K, Schindl M, Gnant M. 4th Austrian pancreas day: a summary of the surgical management of exocrine pancreatic neoplasms. Eur Surg 2013;45:277-81. [DOI: 10.1007/s10353-013-0229-5] [Reference Citation Analysis]
32 Byeon HJ, Choi SH, Choi JS, Kim I, Shin BS, Lee ES, Park E, Lee KC, Youn YS. Four-arm PEG cross-linked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer. Acta Biomaterialia 2014;10:142-50. [DOI: 10.1016/j.actbio.2013.08.046] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
33 Xu Y, Karmakar A, Heberlein WE, Mustafa T, Biris AR, Biris AS. Multifunctional magnetic nanoparticles for synergistic enhancement of cancer treatment by combinatorial radio frequency thermolysis and drug delivery. Adv Healthc Mater 2012;1:493-501. [PMID: 23184783 DOI: 10.1002/adhm.201200079] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
34 Middleton G, Ghaneh P, Costello E, Greenhalf W, Neoptolemos JP. New treatment options for advanced pancreatic cancer. Expert Rev Gastroenterol Hepatol 2008;2:673-96. [PMID: 19072345 DOI: 10.1586/17474124.2.5.673] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
35 Segelov E, Lordick F, Goldstein D, Chantrill LA, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price TJ. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Rev Anticancer Ther 2017;17:951-64. [PMID: 28817982 DOI: 10.1080/14737140.2017.1369882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
36 Calvo FA, Valentini V. Radiotherapy for pancreatic cancer: Systematic nihilism or intraoperative realism. Radiotherapy and Oncology 2008;87:314-7. [DOI: 10.1016/j.radonc.2008.03.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
37 Adamu M, Nitschke P, Petrov P, Rentsch A, Distler M, Reissfelder C, Welsch T, Saeger H, Weitz J, Rahbari NN. Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. Pancreatology 2018;18:585-91. [DOI: 10.1016/j.pan.2018.05.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem J, Conroy T, Arnold D. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2015;26:v56-68. [DOI: 10.1093/annonc/mdv295] [Cited by in Crossref: 525] [Cited by in F6Publishing: 477] [Article Influence: 75.0] [Reference Citation Analysis]
39 Ogawa K, Karasawa K, Ito Y, Ogawa Y, Jingu K, Onishi H, Aoki S, Wada H, Kokubo M, Ogo E, Etoh H, Kazumoto T, Takayama M, Nemoto K, Nishimura Y; JROSG Working Subgroup of Gastrointestinal Cancers. Intraoperative radiotherapy for unresectable pancreatic cancer: a multi-institutional retrospective analysis of 144 patients. Int J Radiat Oncol Biol Phys 2011;80:111-8. [PMID: 20598450 DOI: 10.1016/j.ijrobp.2010.01.065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
40 Li JL, Cai Y, Zhang SW, Xiao SW, Li XF, Duan YJ, Li YH, Xu B, Yan K. Combination of Recombinant Adenovirus-p53 with Radiochemotherapy in Unresectable Pancreatic Carcinoma. Chin J Cancer Res 2011;23:194-200. [PMID: 23467436 DOI: 10.1007/s11670-011-0194-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
41 Shoji H, Miura N, Ueno H, Honda K. Measurement of copy number of ACTN4 to optimize the therapeutic strategy for locally advanced pancreatic cancer. Pancreatology 2018;18:624-9. [PMID: 29921500 DOI: 10.1016/j.pan.2018.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Kim J, Lim JH, Kim JH, Im S, Chie EK, Hwang J, Kim T, Bang Y, Ha SW, Yoon YB. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. Cancer Chemother Pharmacol 2012;70:381-9. [DOI: 10.1007/s00280-012-1918-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
43 Gamblin TC, Egorin MJ, Zuhowski EG, Lagattuta TF, Herscher LL, Russo A, Libutti SK, Alexander HR, Dedrick RL, Bartlett DL. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. Cancer Chemother Pharmacol 2008;62:647-53. [PMID: 18040687 DOI: 10.1007/s00280-007-0647-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
44 Teo M, Crotty GF, O'Súilleabháin C, Ridgway PF, Conlon KC, Power DG, McDermott RS. Identification of distinct phenotypes of locally advanced pancreatic adenocarcinoma. J Gastrointest Cancer 2013;44:73-8. [PMID: 22829058 DOI: 10.1007/s12029-012-9419-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Kircher SM, Krantz SB, Nimeiri HS, Mulcahy MF, Munshi HG, Benson AB. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients. Expert Rev Anticancer Ther. 2011;11:1555-1565. [PMID: 21999129 DOI: 10.1586/era.11.125] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
46 Lam AP, Sparano JA, Vinciguerra V, Ocean AJ, Christos P, Hochster H, Camacho F, Goel S, Mani S, Kaubisch A. Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am J Clin Oncol 2010;33:121-4. [PMID: 19738452 DOI: 10.1097/COC.0b013e3181a31920] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
47 Torgeson A, Tao R, Garrido-Laguna I, Willen B, Dursteler A, Lloyd S. Large database utilization in health outcomes research in pancreatic cancer: an update. J Gastrointest Oncol 2018;9:996-1004. [PMID: 30603118 DOI: 10.21037/jgo.2018.05.15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
48 Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Zerbi A, Nicoletti R, Mazza E, Arcidiacono PG, Di Carlo V, Villa E. Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2009;64:1253-9. [PMID: 19381632 DOI: 10.1007/s00280-009-0995-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
49 O'Sullivan S, Cagney DN. The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective. Ir J Med Sci 2018;187:887-94. [PMID: 29423821 DOI: 10.1007/s11845-018-1755-8] [Reference Citation Analysis]
50 Yao J, Tang YC, Yi B, Yang J, Chai Y, Yin N, Zhang ZX, Wei YJ, Li DC, Zhou J. Signature of gene aberrant alternative splicing events in pancreatic adenocarcinoma prognosis. J Cancer 2021;12:3164-79. [PMID: 33976726 DOI: 10.7150/jca.48661] [Reference Citation Analysis]
51 Stump CT, Roehle K, Manjarrez Orduno N, Dougan SK. Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer. Open Biol 2021;11:210245. [PMID: 34784792 DOI: 10.1098/rsob.210245] [Reference Citation Analysis]
52 Chiang KC, Yu CC, Chen JR, Huang YT, Huang CC, Yeh CN, Tsai CS, Chen LW, Chen HC, Hsu JT, Wang CH, Chen HY. Oncocytic-type intraductal papillary mucinous neoplasm (IPMN)-derived invasive oncocytic pancreatic carcinoma with brain metastasis - a case report. World J Surg Oncol 2012;10:138. [PMID: 22776211 DOI: 10.1186/1477-7819-10-138] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
53 Lee JM, Lee HS, Hyun JJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Chun HJ, Um SH, Kim CD. Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol 2016; 8(7): 555-562 [PMID: 27559435 DOI: 10.4251/wjgo.v8.i7.555] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
54 Kwon W, Thomas A, Kluger MD. Irreversible electroporation of locally advanced pancreatic cancer. Semin Oncol 2021:S0093-7754(21)00009-9. [PMID: 33648735 DOI: 10.1053/j.seminoncol.2021.02.004] [Reference Citation Analysis]
55 Glinka J, Diaz F, Alva A, Mazza O, Sanchez Claria R, Ardiles V, de Santibañes E, Pekolj J, de Santibañes M. Use of radiotherapy in patients with palliative double bypass for locally advanced pancreatic adenocarcinoma. Radiat Oncol J 2018;36:210-7. [PMID: 30309212 DOI: 10.3857/roj.2018.00206] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Ch’ang H, Lin Y, Wang H, Chiu Y, Chang M, Hsu C, Tien Y, Chen J, Hsieh R, Lin P, Shan Y, Cheng A, Chang J, Whang-peng J, Hwang T, Chen L. Induction Chemotherapy With Gemcitabine, Oxaliplatin, and 5-Fluorouracil/Leucovorin Followed by Concomitant Chemoradiotherapy in Patients With Locally Advanced Pancreatic Cancer: A Taiwan Cooperative Oncology Group Phase II Study. International Journal of Radiation Oncology*Biology*Physics 2011;81:e749-57. [DOI: 10.1016/j.ijrobp.2010.10.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
57 Gutt R, Liauw SL, Weichselbaum RR. The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol. 2010;7:437-447. [PMID: 20628346 DOI: 10.1038/nrgastro.2010.98] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
58 Girard N, Mornex F, Bossard N, Ychou M, Chauffert B, Wautot V. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial. Int J Radiat Oncol Biol Phys. 2010;77:1426-1432. [PMID: 20056351 DOI: 10.1016/j.ijrobp.2009.06.053] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
59 Goetze RG, Buchholz SM, Ou N, Zhang Q, Patil S, Schirmer M, Singh SK, Ellenrieder V, Hessmann E, Lu QB, Neesse A. Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer. Cells 2019;8:E563. [PMID: 31181844 DOI: 10.3390/cells8060563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
60 Nour AA, Alaradi A, Mohamed A, Altuwaijri S, Rudat V. Intensity modulated radiotherapy of upper abdominal malignancies: dosimetric comparison with 3D conformal radiotherapy and acute toxicity. Radiat Oncol 2013;8:207. [PMID: 24007346 DOI: 10.1186/1748-717X-8-207] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
61 Bouchart C, Navez J, Closset J, Hendlisz A, Van Gestel D, Moretti L, Van Laethem JL. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? Ther Adv Med Oncol 2020;12:1758835920936093. [PMID: 32684987 DOI: 10.1177/1758835920936093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
62 Laurent S, Monsaert E, Boterberg T, Demols A, Borbath I, Polus M, Hendlisz A, de Hemptinne B, Mahin C, Scalliet P, Van Laethem J, Peeters M. Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I–II study. Annals of Oncology 2009;20:1369-74. [DOI: 10.1093/annonc/mdp005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
63 Campen CJ, Dragovich T, Baker AF. Management strategies in pancreatic cancer. Am J Health Syst Pharm 2011;68:573-84. [PMID: 21411798 DOI: 10.2146/ajhp100254] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
64 Yoshida A, Kitayama Y, Kiguchi K, Yamada T, Akasaka H, Sasaki R, Takeuchi T. Gold Nanoparticle-Incorporated Molecularly Imprinted Microgels as Radiation Sensitizers in Pancreatic Cancer. ACS Appl Bio Mater 2019;2:1177-83. [DOI: 10.1021/acsabm.8b00766] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
65 Chen Y, Zhu H, Wang Y, Song Y, Zhang P, Wang Z, Gao J, Li Z, Du Y. MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor. Technol Cancer Res Treat 2019;18:1533033818824314. [PMID: 30803373 DOI: 10.1177/1533033818824314] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
66 Tomasello G, Ghidini M, Ghidini A, Trevisan F, Celotti A, Russo A, Gambini D, Indini A, Rijavec E, Bareggi C, Galassi B, Petrelli F. Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies. Radiother Oncol 2021;164:13-9. [PMID: 34509562 DOI: 10.1016/j.radonc.2021.09.001] [Reference Citation Analysis]
67 Goldsmith C, Plowman PN, Green MM, Dale RG, Price PM. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity. Radiat Oncol. 2018;13:204. [PMID: 30340643 DOI: 10.1186/s13014-018-1138-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
68 Yu X, Zhang Y, Chen C, Yao Q, Li M. Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta. 2010;1805:97-104. [PMID: 19853645 DOI: 10.1016/j.bbcan.2009.10.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 32] [Article Influence: 1.2] [Reference Citation Analysis]
69 Ishiguro S, Kawabata A, Zulbaran-Rojas A, Monson K, Uppalapati D, Ohta N, Inui M, Pappas CG, Tzakos AG, Tamura M. Co-treatment with a C1B5 peptide of protein kinase Cγ and a low dose of gemcitabine strongly attenuated pancreatic cancer growth in mice through T cell activation. Biochem Biophys Res Commun 2018;495:962-8. [PMID: 29155177 DOI: 10.1016/j.bbrc.2017.11.102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
70 Glissen Brown JR, Perumpail RB, Duran JF, Bharadwaj S, Baran B, Becq A, Hurwitz M, McLaughlin M, Kaplan ID, Cohen J, Gabr M, Pleskow DK, Sawhney MS, Berzin TM. Preloaded 22-gauge fine-needle system facilitates placement of a higher number of fiducials for image-guided radiation therapy compared with traditional backloaded 19-gauge approach. Gastrointest Endosc 2021:S0016-5107(21)01405-X. [PMID: 34081967 DOI: 10.1016/j.gie.2021.05.035] [Reference Citation Analysis]
71 Ogawa K, Ito Y, Karasawa K, Ogawa Y, Onishi H, Kazumoto T, Shibuya K, Shibuya H, Okuno Y, Nishino S, Ogo E, Uchida N, Karasawa K, Nemoto K, Nishimura Y. Patterns of Radiotherapy Practice for Pancreatic Cancer in Japan: Results of the Japanese Radiation Oncology Study Group (JROSG) Survey. International Journal of Radiation Oncology*Biology*Physics 2010;77:743-50. [DOI: 10.1016/j.ijrobp.2009.05.063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
72 Sharp L, Carsin A, Cronin-fenton D, O’driscoll D, Comber H. Is there under-treatment of pancreatic cancer? Evidence from a population-based study in Ireland. European Journal of Cancer 2009;45:1450-9. [DOI: 10.1016/j.ejca.2009.01.033] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
73 Zhang X, Liu J, Zhang P, Dai L, Wu Z, Wang L, Cao M, Jiang J. Silibinin induces G1 arrest, apoptosis and JNK/SAPK upregulation in SW1990 human pancreatic cancer cells. Oncol Lett 2018;15:9868-76. [PMID: 29805688 DOI: 10.3892/ol.2018.8541] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
74 Lambrecht M, Haustermans K. Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. Radiotherapy and Oncology 2010;96:339-46. [DOI: 10.1016/j.radonc.2010.07.019] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
75 Hudson E, Hurt C, Mort D, Brewster AE, Iqbal N, Joseph G, Crosby TD, Mukherjee S. Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment. Clin Oncol (R Coll Radiol). 2010;22:27-35. [PMID: 19896352 DOI: 10.1016/j.clon.2009.09.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
76 Salem MS, Abdel Aziz YM, Elgawish MS, Said MM, Abouzid KA. Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines. Bioorganic Chemistry 2020;94:103472. [DOI: 10.1016/j.bioorg.2019.103472] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
77 Osawa R, Tsunoda T, Yoshimura S, Watanabe T, Miyazawa M, Tani M, Takeda K, Nakagawa H, Nakamura Y, Yamaue H. Identification of HLA-A24-restricted novel T Cell epitope peptides derived from P-cadherin and kinesin family member 20A. J Biomed Biotechnol 2012;2012:848042. [PMID: 22778556 DOI: 10.1155/2012/848042] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
78 Ryu JK. Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer. Korean J Gastroenterol 2015;66:150. [DOI: 10.4166/kjg.2015.66.3.150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
79 Chavalitdhamrong D, DiMaio CJ, Siersema PD, Wagh MS. Technical advances in endoscopic ultrasound-guided fiducial placement for the treatment of pancreatic cancer. Endosc Int Open 2015;3:E373-7. [PMID: 26355267 DOI: 10.1055/s-0034-1392274] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
80 Schwartz DL, Bankson JA, Lemos R Jr, Lai SY, Thittai AK, He Y, Hostetter G, Demeure MJ, Von Hoff DD, Powis G. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 2010;9:2057-67. [PMID: 20587661 DOI: 10.1158/1535-7163.MCT-09-0768] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
81 Rosati LM, Herman JM. Role of Stereotactic Body Radiotherapy in the Treatment of Elderly and Poor Performance Status Patients With Pancreatic Cancer. J Oncol Pract 2017;13:157-66. [PMID: 28282277 DOI: 10.1200/JOP.2016.020628] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
82 Perone JA, Riall TS, Olino K. Palliative Care for Pancreatic and Periampullary Cancer. Surg Clin North Am 2016;96:1415-30. [PMID: 27865285 DOI: 10.1016/j.suc.2016.07.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
83 Su YY, Chiu YF, Li CP, Yang SH, Lin J, Lin SJ, Chang PY, Chiang NJ, Shan YS, Ch'ang HJ, Chen LT. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study. Br J Cancer 2021. [PMID: 34921230 DOI: 10.1038/s41416-021-01649-7] [Reference Citation Analysis]
84 Lin YK, Hsieh MC, Chang CL, Chow JM, Yuan KS, Wu ATH, Wu SY. Intensity-modulated radiotherapy with systemic chemotherapy improves survival in patients with nonmetastatic unresectable pancreatic adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study. Radiother Oncol 2018;129:326-32. [PMID: 30082144 DOI: 10.1016/j.radonc.2018.07.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
85 Seo Y, Kim MS, Yoo S, Cho C, Yang K, Yoo H, Choi C, Lee D, Kim J, Kim MS. Stereotactic body radiation therapy boost in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2009;75:1456-1461. [PMID: 19783379 DOI: 10.1016/j.ijrobp.2009.01.042] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
86 Chua Y, Zalcberg J. Pancreatic cancer—is the wall crumbling? Annals of Oncology 2008;19:1224-30. [DOI: 10.1093/annonc/mdn063] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
87 Bouchard M, Amos RA, Briere TM, Beddar S, Crane CH. Dose escalation with proton or photon radiation treatment for pancreatic cancer. Radiother Oncol. 2009;92:238-243. [PMID: 19454367 DOI: 10.1016/j.radonc.2009.04.015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
88 Morak MJ, Hermans JJ, Smeenk HG, Renders WM, Nuyttens JJ, Kazemier G, van Eijck CH. Staging for locally advanced pancreatic cancer. Eur J Surg Oncol 2009;35:963-8. [PMID: 19246172 DOI: 10.1016/j.ejso.2009.01.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
89 Henry A, Ryder W, Moore C, Sherlock D, Geh J, Dunn P, Price P. Chemoradiotherapy for Locally Advanced Pancreatic Cancer: a Radiotherapy Dose Escalation and Organ Motion Study. Clinical Oncology 2008;20:541-7. [DOI: 10.1016/j.clon.2008.03.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
90 Lim JY, Cho JH, Lee SJ, Lee DK, Yoon DS, Cho JY. Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer. Cancer Res Treat. 2015;47:266-273. [PMID: 25327494 DOI: 10.4143/crt.2013.158] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
91 Maluta S, Schaffer M, Pioli F, Dall'oglio S, Pasetto S, Schaffer PM, Weber B, Giri MG. Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer : an open-label comparative cohort trial.Strahlenther Onkol. 2011;187:619-625. [PMID: 21932025 DOI: 10.1007/s00066-011-2226-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
92 Sahora K, Kuehrer I, Schindl M, Koelblinger C, Goetzinger P, Gnant M. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg. 2011;35:1580-1589. [PMID: 21523499 DOI: 10.1007/s00268-011-1113-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
93 Bjerregaard JK, Mortensen MB, Jensen HA, Fristrup C, Svolgaard B, Schønnemann KR, Hansen TP, Nielsen M, Johansen J, Pfeiffer P. Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer. Radiother Oncol 2009;92:226-30. [PMID: 19435643 DOI: 10.1016/j.radonc.2009.04.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
94 Neoptolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E, Moore M, Padbury R, Doi R, Smith D, Büchler MW. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 2009;100:246-50. [PMID: 19127260 DOI: 10.1038/sj.bjc.6604838] [Cited by in Crossref: 149] [Cited by in F6Publishing: 135] [Article Influence: 11.5] [Reference Citation Analysis]
95 Gong J, Tuli R, Shinde A, Hendifar AE. Meta-analyses of treatment standards for pancreatic cancer. Mol Clin Oncol 2016;4:315-25. [PMID: 26998283 DOI: 10.3892/mco.2015.716] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
96 Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197:466-472. [PMID: 18639229 DOI: 10.1016/j.amjsurg.2007.12.057] [Cited by in Crossref: 253] [Cited by in F6Publishing: 254] [Article Influence: 18.1] [Reference Citation Analysis]
97 Williams M, Drinkwater K. Radiotherapy in England in 2007: Modelled Demand and Audited Activity. Clinical Oncology 2009;21:575-90. [DOI: 10.1016/j.clon.2009.07.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
98 Miyamoto DT, Mamon HJ, Ryan DP, Willett CG, Ancukiewicz M, Kobayashi WK, Blaszkowsky L, Fernandez-del Castillo C, Hong TS. Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older. Int J Radiat Oncol Biol Phys. 2010;77:1171-1177. [PMID: 19800182 DOI: 10.1016/j.ijrobp.2009.06.020] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
99 Yu YP, Yu Q, Guo JM, Jiang HT, Di XY, Zhu Y. Effectiveness and security of CT-guided percutaneous implantation of (125)I seeds in pancreatic carcinoma. Br J Radiol. 2014;87:20130642. [PMID: 24734936 DOI: 10.1259/bjr.20130642] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
100 Camus M, Vienne A, Mestas J, Pratico C, Nicco C, Chereau C, Marie J, Moussatov A, Renault G, Batteux F, Lafon C, Prat F. Cavitation-induced release of liposomal chemotherapy in orthotopic murine pancreatic cancer models: A feasibility study. Clinics and Research in Hepatology and Gastroenterology 2019;43:669-81. [DOI: 10.1016/j.clinre.2019.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
101 Higuera O, Ghanem I, Nasimi R, Prieto I, Koren L, Feliu J. Management of pancreatic cancer in the elderly. World J Gastroenterol 2016; 22(2): 764-775 [PMID: 26811623 DOI: 10.3748/wjg.v22.i2.764] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 52] [Article Influence: 11.5] [Reference Citation Analysis]
102 Lee SY, Sissoko M, Hartshorn KL. Update on the Management of Pancreatic Cancer in Older Adults. Curr Oncol Rep 2016;18:60. [PMID: 27492426 DOI: 10.1007/s11912-016-0547-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
103 Barhoumi M, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset J, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L, Chauffert B. Cancer du pancréas localement évolué non resécable : chimioradiothérapie d’induction suivie de chimiothérapie par gemcitabine contre chimiothérapie exclusive par gemcitabine : résultats définitifs de l’étude de phase III 2000–2001de la FFCD et de la SFRO. Cancer/Radiothérapie 2011;15:182-91. [DOI: 10.1016/j.canrad.2010.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
104 Gillmore R, Laurence V, Raouf S, Tobias J, Blackman G, Meyer T, Goodchild K, Collis C, Bridgewater J. Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience. Clin Oncol (R Coll Radiol) 2010;22:564-9. [PMID: 20605709 DOI: 10.1016/j.clon.2010.05.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
105 Gilabert M, Vaccaro MI, Fernandez-Zapico ME, Calvo EL, Turrini O, Secq V, Garcia S, Moutardier V, Lomberk G, Dusetti N, Urrutia R, Iovanna JL. Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs. J Cell Physiol 2013;228:1834-43. [PMID: 23460482 DOI: 10.1002/jcp.24343] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
106 Martin RC. Management of Locally Advanced Pancreatic Cancer. Surgical Clinics of North America 2016;96:1371-89. [DOI: 10.1016/j.suc.2016.07.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
107 Ng IW, Soon YY, Chen D, Tey JCS. Chemoradiotherapy versus chemotherapy for locally advanced unresectable pancreatic cancer: A systematic review and meta-analysis. Asia-Pac J Clin Oncol 2018;14:392-401. [DOI: 10.1111/ajco.12996] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
108 Hamidi T, Algül H, Cano CE, Sandi MJ, Molejon MI, Riemann M, Calvo EL, Lomberk G, Dagorn JC, Weih F. Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis. J Clin Invest. 2012;122:2092-2103. [PMID: 22565310 DOI: 10.1172/jci60144] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 7.7] [Reference Citation Analysis]
109 Moraru IC, Tai A, Erickson B, Li XA. Radiation dose responses for chemoradiation therapy of pancreatic cancer: an analysis of compiled clinical data using biophysical models. Pract Radiat Oncol 2014;4:13-9. [PMID: 24621418 DOI: 10.1016/j.prro.2013.01.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
110 Zeng H, Yu H, Lu L, Jain D, Kidd MS, Saif MW, Chanock SJ, Hartge P, Risch HA; PanScan Consortium. Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. Pancreas 2011;40:657-63. [PMID: 21487324 DOI: 10.1097/MPA.0b013e31821268d1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
111 Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S, Lordick F, Reni M. What treatment in 2017 for inoperable pancreatic cancers? Ann Oncol. 2017;28:1473-1483. [PMID: 28459988 DOI: 10.1093/annonc/mdx174] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
112 Khan GN, di Magliano MP, Simeone DM. New frontiers in pancreatic cancer research. Surg Oncol Clin N Am 2010;19:431-51. [PMID: 20159524 DOI: 10.1016/j.soc.2009.11.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
113 Chang JS, Chiu YF, Yu JC, Chen LT, Ch'ang HJ. The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis. Cancer Res Treat 2018;50:562-74. [PMID: 28602054 DOI: 10.4143/crt.2017.105] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
114 Park J, Yoo G, Heo J. CdSe/ZnS quantum dot encapsulated MoS2 phototransistor for enhanced radiation hardness. Sci Rep 2019;9:1411. [PMID: 30723221 DOI: 10.1038/s41598-018-37902-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
115 Reni M, Sartori N, Mambrini A, Berardi R, Passardi A, Milella M, Cereda S, Tronconi MC, Aprile G, Cordio S. An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change? Anticancer Drugs. 2010;21:459-464. [PMID: 20110805 DOI: 10.1097/cad.0b013e328336f50e] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
116 Combs S, Habermehl D, Werner J, Büchler M, Debus J. Strategien für präoperatives Downsizing bei inoperablem Pankreaskarzinom. Chirurg 2011;82:981-8. [DOI: 10.1007/s00104-011-2129-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
117 Mornex F, Hatime M, Touch S, Elmorabit B, Pigne G, Enachescu C, Diaz O, Elkhoti Y. Radiotherapy of the pancreas: state of the art in 2012. Recent Results Cancer Res 2012;196:89-103. [PMID: 23129368 DOI: 10.1007/978-3-642-31629-6_6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
118 Committee of the Korean clinical practice guideline for pancreatic cancer and National Cancer Center, Korea. Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches. Pancreatology 2021:S1424-3903(21)00155-1. [PMID: 34148794 DOI: 10.1016/j.pan.2021.05.004] [Reference Citation Analysis]
119 Michael M, Price T, Ngan SY, Ganju V, Strickland AH, Muller A, Khamly K, Milner AD, Dilulio J, Matera A, Zalcberg JR, Leong T. A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer. Br J Cancer 2009;100:37-43. [PMID: 19088724 DOI: 10.1038/sj.bjc.6604827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
120 Hawkins M, Tait D. Locally Advanced Non-Metastatic Pancreatic Cancer — Can We Do More? Clinical Oncology 2008;20:532-4. [DOI: 10.1016/j.clon.2008.04.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
121 Tsujimoto A, Sudo K, Nakamura K, Kita E, Hara R, Takayama W, Ishii H, Yamaguchi T. Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. Sci Rep 2019;9:16187. [PMID: 31700023 DOI: 10.1038/s41598-019-52486-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
122 Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013;144:1316-1326. [PMID: 23622141 DOI: 10.1053/j.gastro.2013.01.078] [Cited by in Crossref: 188] [Cited by in F6Publishing: 181] [Article Influence: 20.9] [Reference Citation Analysis]
123 Vieillot S, Azria D, Riou O, Moscardo CL, Dubois JB, Aillères N, Fenoglietto P. Bilateral kidney preservation by volumetric-modulated arc therapy (RapidArc) compared to conventional radiation therapy (3D-CRT) in pancreatic and bile duct malignancies. Radiat Oncol 2011;6:147. [PMID: 22040762 DOI: 10.1186/1748-717X-6-147] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
124 Johung K, Saif MW, Chang BW. Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Int J Radiat Oncol Biol Phys 2012;82:508-18. [PMID: 22075449 DOI: 10.1016/j.ijrobp.2011.08.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
125 He J, Page AJ, Weiss M, Wolfgang CL, Herman JM, Pawlik TM. Management of borderline and locally advanced pancreatic cancer: Where do we stand? World J Gastroenterol 2014; 20(9): 2255-2266 [PMID: 24605025 DOI: 10.3748/wjg.v20.i9.2255] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
126 Tang M, Svirskis D, Leung E, Kanamala M, Wang H, Wu Z. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer? J Control Release 2019;305:89-100. [PMID: 31096017 DOI: 10.1016/j.jconrel.2019.05.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
127 de Geus SWL, Eskander MF, Kasumova GG, Ng SC, Kent TS, Mancias JD, Callery MP, Mahadevan A, Tseng JF. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Cancer. 2017;123:4158-4167. [PMID: 28708929 DOI: 10.1002/cncr.30856] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
128 Ohno I, Eibl G, Odinokova I, Edderkaoui M, Damoiseaux RD, Yazbec M, Abrol R, Goddard WA 3rd, Yokosuka O, Pandol SJ, Gukovskaya AS. Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family. Am J Physiol Gastrointest Liver Physiol 2010;298:G63-73. [PMID: 19762431 DOI: 10.1152/ajpgi.00257.2009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
129 Hamada S, Masamune A, Shimosegawa T. Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer. Front Physiol 2013;4:331. [PMID: 24273517 DOI: 10.3389/fphys.2013.00331] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
130 Martin RCG 2nd. Multi-disciplinary management of locally advanced pancreatic cancer with irreversible electroporation. J Surg Oncol 2017;116:35-45. [PMID: 28475814 DOI: 10.1002/jso.24640] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
131 Kim D, Zhu H, Nassri A, Mokdad A, Kukreja S, Polanco P, Huerta S, Ramzan Z. Survival analysis of veteran patients with pancreatic cancer. J Dig Dis. 2016;17:399-407. [PMID: 27235863 DOI: 10.1111/1751-2980.12361] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
132 Xie D, Xie K. Pancreatic cancer stromal biology and therapy. Genes Dis. 2015;2:133-143. [PMID: 26114155 DOI: 10.1016/j.gendis.2015.01.002] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 10.9] [Reference Citation Analysis]
133 Salgado M, Arévalo S, Hernando O, Martínez A, Yaya R, Hidalgo M. Management of unresectable, locally advanced pancreatic adenocarcinoma. Clin Transl Oncol 2018;20:113-8. [PMID: 28612202 DOI: 10.1007/s12094-017-1679-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
134 Park JK, Kim Y, Kim H, Jeon J, Kim TW, Park JH, Hwnag YI, Lee WJ, Kang JS. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Oncotarget 2016;7:75081-93. [PMID: 27655706 DOI: 10.18632/oncotarget.12057] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
135 Choi M, Fuller CD, Wang SJ, Siddiqi A, Wong A, Thomas CR, Fuss M. Effect of body mass index on shifts in ultrasound-based image-guided intensity-modulated radiation therapy for abdominal malignancies. Radiotherapy and Oncology 2009;91:114-9. [DOI: 10.1016/j.radonc.2008.08.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
136 Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset J, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Annals of Oncology 2008;19:1592-9. [DOI: 10.1093/annonc/mdn281] [Cited by in Crossref: 451] [Cited by in F6Publishing: 385] [Article Influence: 32.2] [Reference Citation Analysis]
137 Sung HY, Jung SE, Cho SH, Zhou K, Han JY, Han ST, Kim JI, Kim JK, Choi JY, Yoon SK. Long-term outcome of high-intensity focused ultrasound in advanced pancreatic cancer. Pancreas. 2011;40:1080-1086. [PMID: 21926543 DOI: 10.1097/mpa.0b013e31821fde24] [Cited by in Crossref: 59] [Cited by in F6Publishing: 29] [Article Influence: 5.9] [Reference Citation Analysis]
138 Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009;27:2269-2277. [PMID: 19307501 DOI: 10.1200/jco.2008.19.7921] [Cited by in Crossref: 174] [Cited by in F6Publishing: 60] [Article Influence: 13.4] [Reference Citation Analysis]
139 Xu J, Singh A, Amiji MM. Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer. BMC Cancer. 2014;14:75. [PMID: 24507760 DOI: 10.1186/1471-2407-14-75] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
140 Faris JE, Wo JY. The controversial role of chemoradiation for patients with locally advanced pancreatic cancer. Oncologist 2013;18:981-5. [PMID: 24021761 DOI: 10.1634/theoncologist.2013-0270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
141 Brunner TB, Scott-Brown M. The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol. 2010;5:64. [PMID: 20615227 DOI: 10.1186/1748-717x-5-64] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
142 Xu Z, Hu K, Bailey P, Springfeld C, Roth S, Kurilov R, Brors B, Gress T, Buchholz M, An J, Wei K, Peccerella T, Büchler MW, Hackert T, Neoptolemos JP. Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Front Cell Dev Biol 2021;9:743908. [PMID: 34805152 DOI: 10.3389/fcell.2021.743908] [Reference Citation Analysis]
143 DI Marco M, Macchini M, Vecchiarelli S, Casadei R, Pezzilli R, Fanti S, Zanoni L, Calculli L, Barbieri E, Santini D, DI Cicilia R, Brandi G, Biasco G. Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases. Oncol Lett 2011;2:195-200. [PMID: 22866063 DOI: 10.3892/ol.2011.253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]